Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 1-year average of 138.63%, near the low end of its 1-year range (0.00%–693.16%).
100.00% below its 12-month average of 138.63%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 693.16%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
138.63%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 734 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Nautilus Biotechnolgy, Inc.
Market Cap
$245.13M
Gross Margin
0.00%
TTM Avg
138.63%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$246.29M
Gross Margin
47.33%
TTM Avg
49.83%
3Y Avg
36.19%
5Y Avg
24.13%
Market Cap
$243.62M
Gross Margin
N/A
TTM Avg
31.32%
3Y Avg
30.59%
5Y Avg
32.68%
Market Cap
$243.66M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$243.34M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$240.04M
Gross Margin
53.14%
TTM Avg
76.57%
3Y Avg
72.53%
5Y Avg
61.83%
Market Cap
$239.69M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $245.13M | 0.00% | 138.63% | 0.00% | 0.00% |
| Invivyd, Inc. (IVVD)vs › | $246.00M | 91.35% | 93.31% | 46.66% | 31.10% |
| Q32 Bio Inc. (QTTB)vs › | $246.15M | 99.84% | 50.00% | 75.00% | 50.00% |
| Quantum-Si incorporated (QSI)vs › | $246.29M | 47.33% | 49.83% | 36.19% | 24.13% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A | 31.32% | 30.59% | 32.68% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Galectin Therapeutics Inc. (GALT)vs › | $243.34M | 0.00% | 0.00% | 0.00% | 0.00% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.04M | 53.14% | 76.57% | 72.53% | 61.83% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.69M | 79.48% | 71.93% | 74.52% | 72.98% |
| InflaRx N.V. (IFRX)vs › | $238.61M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 693.16% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
